dipyridamole has been researched along with Familial Combined Hyperlipidemia in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pitkänen, OP | 1 |
| Nuutila, P | 1 |
| Raitakari, OT | 1 |
| Porkka, K | 1 |
| Iida, H | 1 |
| Nuotio, I | 1 |
| Rönnemaa, T | 1 |
| Viikari, J | 1 |
| Taskinen, MR | 1 |
| Ehnholm, C | 1 |
| Knuuti, J | 1 |
1 trial available for dipyridamole and Familial Combined Hyperlipidemia
| Article | Year |
|---|---|
Coronary flow reserve in young men with familial combined hyperlipidemia.
Topics: Adult; Blood Flow Velocity; Blood Pressure; Body Mass Index; Coronary Circulation; Dipyridamole; Hea | 1999 |